首页 › 膀胱癌 › 俄克拉荷马州 › Oklahoma City
Oklahoma City OK 膀胱癌临床试验
11项针对 膀胱癌的研究正在 Oklahoma City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中欢迎健康志愿者
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Mercy Hospital Oklahoma City, Oklahoma City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- University of Oklahoma - Health Sciences Center, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
招募中3 期
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
招募中2 期
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
招募中1 期
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
招募中观察性研究
- Mercy Hospital - OKC, Oklahoma City
其他城市的 膀胱癌试验
- New York City, NY35 项研究
- Houston, TX31 项研究
- Nashville, TN31 项研究
- Dallas, TX27 项研究
- Washington, DC26 项研究
- Boston, MA26 项研究
- Baltimore, MD24 项研究
- Los Angeles, CA24 项研究
- St. Louis, MO22 项研究
- Seattle, WA21 项研究
- Edison, NJ21 项研究
- Philadelphia, PA21 项研究
Oklahoma City的其他研究
- 非小细胞肺癌28 项研究
- 卵巢癌28 项研究
- 子宫内膜癌25 项研究
- 结直肠癌22 项研究
- 前列腺癌21 项研究
- 肺癌19 项研究
- 乳腺癌17 项研究
- 转移性癌症16 项研究
- 癌症（所有类型）14 项研究
- 急性髓系白血病14 项研究
- 头颈鳞状细胞癌13 项研究
- 胰腺癌11 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。